fragile X syndrome

fragile X syndrome
Field	Medical genetics, Pediatrics, Neurology

fragile X syndrome. It is the most common inherited form of intellectual disability and a leading genetic cause of autism spectrum disorder. The condition results from a mutation on the X chromosome and presents with a distinct constellation of physical, behavioral, and cognitive features. Research into the syndrome has been pivotal in understanding trinucleotide repeat disorders and neurodevelopmental disorders.

Signs and symptoms

Common physical characteristics include a long face, prominent ears, and macroorchidism. Individuals often exhibit significant intellectual disability, which can range from mild to severe, alongside pronounced attention deficit hyperactivity disorder and social anxiety. Stereotypical behaviors such as hand-flapping and perseveration are frequent, and many meet diagnostic criteria for autism spectrum disorder. Other medical concerns can include mitral valve prolapse, seizure disorder, and connective tissue dysplasia, leading to joint hypermobility and otitis media.

Genetics

The syndrome is caused by a dynamic mutation—an expansion of a CGG triplet repeat—within the FMR1 gene located on the X chromosome. A full mutation, typically involving over 200 repeats, leads to DNA methylation and histone modification that silence the gene, preventing production of FMRP. This protein is crucial for normal synaptic plasticity and neuronal development. The premutation allele, with 55 to 200 repeats, carries risks for Fragile X-associated tremor/ataxia syndrome and Fragile X-associated primary ovarian insufficiency.

Diagnosis

Diagnosis is confirmed through DNA analysis to assess the number of CGG triplet repeats in the FMR1 gene, typically via Southern blot or polymerase chain reaction methodologies. Cytogenetic testing for a fragile site on the X chromosome is now largely historical. Diagnostic evaluation is often prompted by developmental delay, and American College of Medical Genetics guidelines recommend testing for individuals with unexplained intellectual disability or autism spectrum disorder. Prenatal diagnosis is available through chorionic villus sampling or amniocentesis.

Management

Management is multidisciplinary, involving pediatrics, neurology, speech-language pathology, and occupational therapy. While no cure exists, interventions focus on behavioral therapy, special education programs, and medications to manage symptoms like attention deficit hyperactivity disorder or mood disorder. Research into targeted treatments, including mGluR5 antagonists and GABAergic agents, is ongoing through clinical trials coordinated by entities like the FRAXA Research Foundation. Regular monitoring for complications such as seizure disorder and mitral valve prolapse is standard.

Epidemiology

It is estimated to affect approximately 1 in 4,000 males and 1 in 8,000 females worldwide, making it the most common monogenic cause of autism spectrum disorder. The premutation is far more prevalent, found in about 1 in 150 females and 1 in 450 males. There is no known ethnic or racial predilection, and the condition has been reported in all populations studied, including those in the United States, Europe, and Asia. The Centers for Disease Control and Prevention supports public health tracking and research into its prevalence.

History

The condition was first described in 1943 by James Purdon Martin and Julia Bell in a report to the Royal Society of Medicine. The cytogenetic hallmark, a fragile site on the X chromosome, was identified in 1969 by Herbert Lubs using karyotype analysis. The responsible FMR1 gene was isolated in 1991 by collaborative teams including scientists from Baylor College of Medicine and the University of Amsterdam. This discovery, supported by the National Institutes of Health, fundamentally advanced the understanding of trinucleotide repeat disorders and genomic imprinting.

Category:Genetic disorders Category:Neurological disorders Category:Pediatrics